Gsa Capital Partners LLP Viridian Therapeutics, Inc.\De Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
A detailed history of Gsa Capital Partners LLP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Gsa Capital Partners LLP holds 11,332 shares of VRDN stock, worth $203,749. This represents 0.02% of its overall portfolio holdings.
Number of Shares
11,332Holding current value
$203,749% of portfolio
0.02%Shares
2 transactions
Others Institutions Holding VRDN
# of Institutions
186Shares Held
77.7MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$85.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$82.6 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$69.8 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$67.4 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$62 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $717M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...